Acorda(ACOR) - Get Report shares fell Thursday after the company suffered a first quarter earnings miss. Net revenue  for its Ampyra totaled $112 million, short of the $121 million consensus. The company did re-affirm guidance for full-year Ampyra sales in the range of $535-545 million.

The shares closed at $15.55, down 5.76%.

The experimental Parkinson's disease drug CVT-301 has a new brand name, Inbrija, and will be filed with the FDA in the second quarter. A European approval filing will be completed by the end of the year. The company decided not to move an experimental acute migraine drug CVT-427 into a phase II study.

Acorda slashed $50 million in operating expenses for 2017 in a restructuring that terminated a large number of employees earlier this quarter. CEO Ron Acorda still hasn't said if he's taking a pay cut but the company's proxy statement indicates he's getting a 3% bump in his 2017 salary.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.